InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
11 mai 2021 16h30 HE
|
InflaRx N.V.
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of careEU IXCHANGE...
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study in Pyoderma Gangraenosum
15 avr. 2021 07h30 HE
|
InflaRx N.V.
Target enrollment of 18 patients reached across three different dose groupsInterim results will be available by the end of 2021 with final results expected in 2022Initial positive data from the first...
InflaRx Reports Full Year 2020 Financial & Operating Results
25 mars 2021 06h30 HE
|
InflaRx N.V.
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021Phase III trial in Severe COVID-19 is ongoing and recruiting...
InflaRx to Present at Upcoming Investor Conferences
03 mars 2021 07h30 HE
|
InflaRx N.V.
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that management will present at...
InflaRx Announces Closing of $75 Million Public Offering of Common Shares and One-Year Warrants
01 mars 2021 16h01 HE
|
InflaRx N.V.
JENA, Germany, March 01, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
InflaRx Announces Pricing of $75 Million Public Offering of Common Shares and One-Year Warrants
25 févr. 2021 08h30 HE
|
InflaRx N.V.
JENA, Germany, Feb. 25, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
24 févr. 2021 16h01 HE
|
InflaRx N.V.
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Presentation of New C5a and Vilobelimab (IFX-1) Data from Phase IIB SHINE Study at the 2021 Virtual European Hidradenitis Suppurativa Foundation Conference
11 févr. 2021 07h30 HE
|
InflaRx N.V.
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patientsVilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction...
InflaRx Provides Update on Vilobelimab (IFX-1) Development
11 janv. 2021 07h30 HE
|
InflaRx N.V.
Multiple data readouts expected in 2021Phase II trial in patients with cutaneous squamous cell carcinoma expected to start in the first half of 2021 JENA, Germany, Jan. 11, 2021 (GLOBE...
InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference
07 janv. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...